-+ 0.00%
-+ 0.00%
-+ 0.00%

Acotec Scientific expects H1 net loss up to RMB 80.9 million, swings from profit

PUBT·08/12/2026 10:27:10
Listen to the news
Acotec Scientific expects H1 net loss up to RMB 80.9 million, swings from profit
  • Acotec guided for a net loss of no more than RMB 80.9 million for the six months ended June 30, 2026.
  • That compares with net profit of about RMB 88.6 million a year earlier.
  • Forecast reflects discontinuation of the U.S. clinical trial program for AcoArt Litos paclitaxel-coated PTA balloon catheter.
  • Exit triggered one-off non-cash impairment and termination-related provisions totaling about RMB 150.8 million.
  • Interim results are expected to be published by end-August 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acotec Scientific Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260812-12281620), on August 12, 2026, and is solely responsible for the information contained therein.